Glucagon like peptide-1 (GLP-1) dynamics following bariatric surgery: A signpost to a new frontier

Current Diabetes Reviews

Volumn 9, Issue 2, 2013, Pages 93-101

  Neff, K J ^a   O'Shea, D ^b   le Roux, C W ^a,c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bariatric surgery; GLP 1; Glucagon like peptide 1; Incretins

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INCRETIN;

BILIOPANCREATIC BYPASS; BODY MASS; CIRCADIAN RHYTHM; CROSS-SECTIONAL STUDY; FOOD INTAKE; GASTRIC BANDING; GASTROJEJUNOSTOMY; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; HYPERINSULINEMIA; INCISIONAL HERNIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONGITUDINAL STUDY; LOW CALORY DIET; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PARTIAL GASTRECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; STOMACH POUCH; STOMACH TUBE; WEIGHT REDUCTION; WOUND INFECTION;

EID: 84877802341     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811309020001     Document Type: Review

References (115)

1. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Suaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011; (10): CD006423.
2. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90(11): 5991-7.
3. Linnebjerg H, Kothare PA, Skrivanek Z, et.al. Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med. 2006; 23(3): 240-5.
4. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 (proglucagon-[78-107]amide) on endocrine secretion from pig pancreas, antrum and non-antrum stomach. Endocrinology. 1988; 123(4): 2009-13.
5. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997; 273(5 pt 1): e981-9.
6. Fetner R, McGinty J, Russell C, Pi-Sunyer FX, Laferrère B. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis. 2005; 1(6): 589-97.
7. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001; 25(6): 781-92.
8. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281(1): e155-61.
9. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg. 2009; 19(12): 1605-11.
10. Smith BR, Schauer P, Nguyen NT. Surgical approaches to the treatment of obesity: bariatric surgery. Med Clin North Am. 2011; 95(5): 1009-30.
11. Reoch J, Mottillo S, Shimony A, et al. Safety of laparoscopic vs open bariatric surgery: a systematic review and meta-analysis. Arch Surg. 2011; 146(11): 1314-22.
12. O'Brien PE, Dixon JB, Laurie C, Anderson M. A prospective randomized trial of placement of the laparoscopic adjustable gastric band: comparison of the perigastric and pars flaccida pathways. Obes Surg. 2005; 15(6): 820-6.
13. Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011; 301(1): R15-27.
14. Scopinaro N, Gianetta E, Pandolfo N, Anfossi A, Berretti B, Bachi V. [Bilio-pancreatic bypass. Proposal and preliminary experimental study of a new type of operation for the functional surgical treatment of obesity]. Minerva Chir. 1976; 31(10): 560-6.
15. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg. 1998; 8(3): 267-82.
16. Elliot RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993; 138(1): 159-66.
17. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 1996; 38(6): 916-9.
18. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetalogia. 2004; 47(3): 357-66.
19. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008; 57(5): 1340-8.
20. Mingrone G, Nolfe G, Gissey GC, et al. Circadian rhythms of GIP and GLP1 in glucose tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetalogia. 2009; 52(5): 873-81.
21. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011; 54(1): 10-8.
22. Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001; 25(8): 1206-14.
23. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007; 246(5): 780-5.
24. Vidal J, Nicolau J, Romero F, et al. Long-term effects of Roux-en-Y gastric bypass surgery on plasma glucagon-like peptide-1 and islet function in morbidly obese subjects. J Clin Endocrinol Metab. 2009; 94(3): 884-91.
25. Dar MS, Chapman WH, 3rd, Pender JR, et al. GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? Obes Surg. 2012; 22(7): 1077-83.
26. Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-enY gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007; 30(7): 1709-16.
27. de Carvalho CP, Marin DM, de Souza AL, et al. GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg. 2009; 19(3): 313-20.
28. Falken Y, Hellstrom PM, Holst JJ, Naslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. The Journal of clinical endocrinology and metabolism. 2011; 96(7): 2227-35.
29. Neovius M, Narbro K, Keating C, et al. Health care use during 20 years following bariatric surgery. JAMA. 2012; 308(11): 1132-41.
30. Morínigo R, Moizé V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006; 91(5): 1735-40.
31. Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond). 2009; 33(7): 786-95.
32. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007; 3(6): 597-601.
33. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006; 243(1): 108-14.
34. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006; 93(2): 210-5.
35. Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and in-cretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93(7): 2479-85.
36. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass: mechanisms and 2 year outcomes. Ann Surg. 2010; 252(6): 966-71.
37. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabete mellitus. Am Surg. 2004; 70(1): 1-4.
38. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004; 240(2): 236-42.
39. le Roux CW, Borg C, Wallis K, et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg. 2010; 252(1): 50-6.
40. Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obesity surgery. 2011 Jul; 21(7): 896-901.
41. Jorgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab. 2012; 303(1): E122-31.
42. Shak JR, Roper J, Perez-Perez GI, et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg. 2008; 18(9): 1089-96.
43. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292: 1724-37.
44. Sjostrom L, Lindroos AK, Peltonen M: Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. NEJM. 2004; 351(26): 2683-93.
45. Padwal R, Klarenbach S, Wiebe N, et al. Bariatric surgery: a systematic review and network meta-analysis of randomized trials. Obes Rev. 2011; 12(8): 602-21.
46. Bose M, Machineni S, Olivan B, et al. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010; 18(6): 1085-91.
47. Dixon AF, Dixon JB, O'Brien PE. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab. 2005; 90(2): 813-9.
48. Usinger L, Hansen KB, Kristiansen VB, Larsen S, Holst JJ, Knop FK. Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding. Obes Surg. 2011; 21(5): 625-32.
49. Chiellini C, Rubino F, Castagneto M, Nanni G, Mingrone G. The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI <35 kg/m2. Diabetologia. 2009; 52: 1027-30.
50. Guidonel C, Mancol M, Valera-Moral F et al. Mechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery. Diabetes. 2006; 55(7): 2025-31.
51. Valverde I, Puente J, Martín-Duce A et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg. 2005; 15(3): 387-97.
52. Marfella R, Barbieri M, Ruggiero R, et al. Bariatric surgery reduces oxidative stress by blunting 24-h acute glucose fluctuations in type 2 diabetic obese patients. Diabetes Care. 2010; 33(2): 287-9.
53. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG. Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obes Surg. 2007; 17(9): 1193-8.
54. Strader AD, Vahl TP, Jandacek RJ, Woods SC, D'Alessio DA, Seeley RJ. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab. 2005; 288: 447-53.
55. Zhang GY, Wang TT, Cheng ZQ, Feng JB, Hu SY. Resolution of diabetes mellitus by ileal transposition compared with biliopancreatic diversion in a non-obese animal model of type 2 diabetes. Can J Surg. 2011; 54(4): 243-51.
56. Cottam D, Qureshi FG, Mattar SG, et al. Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. Surg Endosc. 2006; 20: 859-63.
57. Omana J, Nguyen S, Herron D, Kini S. Comparison of comorbidity resolution and improvement between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding. Surg Endosc. 2010; 24: 2513-17.
58. Abbatini F, Rizzello M, Casella G, et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc. 2010; 24: 1005-10.
59. Romero F, Nicolau J, Flores L, et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc. 2012; 26(8): 2231-9.
60. Valderas JP, Irribarra V, Rubio L, et al. Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide 1 levels and glucose homeostasis in non-diabetic subjects. Obesity surgery. 2011; 21(7): 902-9.
61. Peterli R, Wölnerhanssen B, Thomas P, et al. Improvement in Glucose Metabolism After Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy: A Prospective Randomized Trial. Ann Surg. 2009; 250(2): 234-41.
62. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. N Eng J Med. 2012; March 26. [Epub before print]
63. Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011; 7(6): 683-90.
64. Chambers AP, Jessen L, Ryan KK, et al. Weight independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology. 2011; 141(3): 950-8.
65. Pereferrer FS, Gonzàlez MH, Rovira AF, et al. Influence of sleeve gastrectomy on several experimental models of obesity: metabolic and hormonal complication. Obes Surg. 2008; 18(1): 97-108.
66. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastro-intestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006; 244: 741-9.
67. Pacheco D, de Luis DA, Romero A, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg. 2007; 194: 221-24.
68. Eldar S, Heneghan HM, Dan O, Kirwan JP, Schauer PR, Brethauer SA. Gastrostomy tube placement in gastric remnant at gastric bypass: a rat model for selective gut stimulation. Surg Obes Relat Dis. 2011; Dec 20. [Epub ahead of print]
69. Dirksen C, Hansen DL, Madsbad S, et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care; 2010. 33: 375-7.
70. Pournaras DJ, Aasheim ET, Bueter M, et al. Effect of bypassing proximal gut on gut hormones involved with glycemic control and weight loss. Surg Obes Relat Dis. 2012; Mar 3. [Epub ahead of print]
71. Hansen EN, Tamboli RA, Isbell JM, et al. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol Gastrointest Liver Physiol. 2011; 300(5): G795-802.
72. Lee WJ, Lee YC, Ser KH, Chen JC, Chen SC. Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. Obes Surg. 2008; 18(9): 1119-25.
73. Kindel TL, Martins PJ, Yoder SM, et al. Bypassing the duodenum does not improve insulin resistance associated with diet-induced obesity in rodents. Obesity (Silver Spring). 2011; 19(2): 380-7.
74. Patriti A, Aisa MC, Annetti C, et al. How the hindgut can cure type 2 diabetes: ileal transposition improves glycaemic metabolism and beta-cell function in Goto-kakizaki rats through an enhanced pro-glucagon gene expression and L-cell number. Surgery. 2007; 142(1): 74-85.
75. Patriti A, Facchiano E, Annetti C, et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg. 2005; 15(9): 1258-64.
76. Wang TT, Hu SY, Gao HD, et al. Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a non-obese rat model of type 2 diabetes by increasing GLP-1. Ann Surg. 2008; 247(6): 968-75.
77. Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest. 1996; 97(1): 92-103.
78. Chaikomin R, Doran S, Jones KL et al. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycaemia in healthy subject. Am J Physiol Endocrinol Metab. 2005; 289(3): 504-7.
79. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005; 329(1): 386-90.
80. Gomez G, Lluis F, Ishizuka J, et al. Bile enhances release of insulin: an incretin-mediated effect. Surgery. 1987; 102(2): 195-9.
81. Adrian TE, Gariballa S, Parekh KA, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. 2012; 55(9): 2343-7.
82. Nakatani H, Kasama K, Oshiro T, et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism. 2009; 58(10): 1400-7.
83. Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012; 153(8): 3613-9.
84. Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, Schoonjans K. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep. 2012; 2: 430.
85. Parker HE, Wallis K, le Roux CW, et al. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol. 2012; 165(2): 414-23.
86. Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology. 1993; 133(1): 233-40.
87. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology. 1999; 140(4): 1687-94.
88. Vahl TP, Tauchi M, Durler TS, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology. 2007; 148(10): 4965-73.
89. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. American journal of physiology Regulatory, integrative and comparative physiology. 2000 Oct; 279(4): R1449-54. PubMed PMID: 11004015.
90. Hira T, Mochida T, Miyashita K, Hara H. GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats. Am J Physiol Gastrointest Liver Physiol. 2009; 297(4): G663-71.
91. Lausier J, Diaz WC, Roskens V, LaRock K, Herzer K, Fong CG, Latour MG, Peshavaria M, Jetton JL. Vagal control of pancreatic ss-cell proliferation. Am J Physiol Endocrinol Metab. 2010; 299(5): E786-93.
92. Bueter M, Lowenstein C, Ashrafian H, Hillebrand J, Bloom SR, Olbers T, Lutz T, le Roux CW. Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass. Obes Surg. 2010; 20(5): 616-22.
93. Shin AC, Zheng H, Berthoud HR. Vagal innervation of the hepatic portal vein and liver is not necessary for Roux-en-Y gastric bypass surgery-induced hypophagia, weight loss, and hypermetabolism. Ann Surg. 2012; 255(2): 294-301.
94. Martin MB, Earle KR. Laparoscopic adjustable gastric banding with truncal vagotomy: any increased weight loss? Surg Endosc. 2011; 25(8): 2522-5.
95. Angrisani L, Cutolo PP, Ciciriello MB, et al. Laparoscopic adjustable gastric banding with truncal vagotomy versus laparoscopic adjustable gastric banding alone: interim results of a prospective randomized trial. Surg Obes Relat Dis. 2009; 5(4): 435-8.
96. Cohen RV, Schiavon CA, Pinheiro JS, Correa J Luiz, Rubino F. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with BMI 22-34: a report of two cases. Surg Obes Relat Dis. 2007; 3(2): 195-7.
97. Garrido-Sanchez L, Murri M, Rivas-Becerra J, et al. Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy. Surg Obes Relat Dis. 2012; 8(2): 145-50.
98. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev. 2003; 19(2): 115-23.
99. Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol. 2010; 159(3): 495-501.
100. Perry T, Holloway HW, Weerasuriya A, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007; 203(2): 293-301.
101. Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetalogia. 2011; 54(11): 2745-54.
102. Higa-Sansone G, Szomstein S, Soto F, Brasecsco O, Cohen C, Rosenthal RJ. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004; 14(8): 1132-4.
103. Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves psoriasis. J Am Acad Dermatol. 2011; 65(1): 198-200.
104. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food in-take in obese subjects by peptide YY3-36. N Engl J Med. 2003; 349(10): 941-8.
105. le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2006; 147(1): 3-8.
106. Evan S. Pamuklar Z, Rosko J, Mahanev P, Jiang N, Park C, Torquati A. Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction. Surg Endosc. 2012; 26(4): 1086-94.
107. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology. 2005; 146(12): 5120-7.
108. Lauritsen KB, Moody AJ, Christensen KC, Lindkaer Jensen S. Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man. Scand J Gastroenterol. 1980; 15(7): 833-40.
109. Sirinek KR, O'Dorisio TM, Hill D, McFee AS. Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery. 1986; 100(4): 781-7.
110. Bose M, Olivan B, Teixeira J, Pi-Sunyer FX, Laferrere B. Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes Surg. 2009; 19(2): 217-29.
111. Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res. 2004; 12(2): 346-50.
112. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003; 88(4): 1594-602.
113. Fruhbeck G, Rotellar F, Hernandez-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 2004; 14(9): 1208-15.
114. Chronaiou A, Tsoli M, Kehagias I, Leotsinidis M, Kalfarentzos F, Alexandrides TK. Lower Ghrelin Levels and Exaggerated Postprandial Peptide-YY, Glucagon-Like Peptide-1, and Insulin Responses, After Gastric Fundus Resection, in Patients Undergoing Roux-en-Y Gastric Bypass: A Randomized Clinical Trial. Obes Surg. 2012; 22(11): 1761-70.
115. Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012; 22(5): 740-8.